The “Watchman” device is an alternative for patients with non-valvular atrial fibrillation at risk for stroke, especially those with a compelling reason not to be on blood thinners.

ALBUQUERQUE, N.M. (KRQE) – The Lovelace Heart Hospital is celebrating the new addition of their 1,000th heart device. Called ...

The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

For patients with atrial fibrillation who need protection from stroke and other complications after ablation, left atrial ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Boston Scientific Corp. (BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the ...

The WATCHMAN FLX device showed superior safety with 8.5% major bleeding ... for stroke risk reduction in patients with ...

Boston Scientific has reported positive three-year data from the OPTION global trial of the WATCHMAN FLX left atrial appendage closure (LAAC) device in individuals with atrial fibrillation ...